Alice T. Shaw, MD, PhD, an attending physician in the Center for Thoracic Cancers at Massachusetts General Hospital, discusses resistance to crizotinib in patients with ALK-positive lung cancer
Alice T. Shaw, MD, PhD, an attending physician in the Center for Thoracic Cancers at Massachusetts General Hospital, discusses resistance to crizotinib in patients with ALK-positive lung cancer.
Learn more about thetreatment of ALK-positive lung cancer > >
Patient Factors Determine Treatment Selection for PD-L1 Negative NSCLC
June 19th 2025During a live event, Neal E. Ready, MD, and participants discussed use of PD-L1 status in non–small cell lung cancer and compared the use of single agent vs doublet immunotherapy in the PD-L1–low setting.
Read More